Generic Medicines Save Money for Patients and Taxpayers | Association for Accessible Medicines
AAM All Access Podcast - AAM CEO Dan Leonard convenes industry and policy experts to explore why the Inflation Reduction Act (f/k/a Build Back Better) reduces generic and biosimilar competition.

Generic Medicines Save Money for Patients and Taxpayers

AAM is the nation’s leading trade association for manufacturers and distributors of generic and biosimilar prescription medicines. Our core mission is to improve the lives of patients by advancing timely access to affordable, FDA-approved generic and biosimilar medicines. Our members provide more than 36,000 jobs at nearly 150 facilities, and manufacture more than 61 billion doses of prescription medicines in the United States every year.

Key Points:

  • Generic drug spending is not what is driving the increase in health care costs.
  • Generic medicines drive savings, not costs.
  • Many drug supply chain entities impact the costs patients pay at the pharmacy counter. Once a generic drug manufacturer sells its products to a wholesaler, the company no longer plays a role in the price of those products.

Download Fact Sheet


Association for Accessible Medicines


Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.